MYC and cancer: Furthermore, CX-5461 works in combination with PIM kinase, mTOR (everolimus), and histone deacetylase (panobinostat) inhibitors in MYC-driven cancer models, through amplifying the inhibition of ribosome biogenesis, protein synthesis, and metabolic homeostasis [186,187,188].